Recently, an RCT to evaluate the efficacy and safety of icatibant, a C1 esterase/kallikrein inhibitor, in severe COVID-19 has been launched [144] and this study may lead to a more rigorous association between COVID-19 infection and bradykinin systems. The gene discussed is KNG1; the disease is COVID-19.